CA3189374A1 - Suppression de liberation de cytokine et de choc cytokinique - Google Patents

Suppression de liberation de cytokine et de choc cytokinique

Info

Publication number
CA3189374A1
CA3189374A1 CA3189374A CA3189374A CA3189374A1 CA 3189374 A1 CA3189374 A1 CA 3189374A1 CA 3189374 A CA3189374 A CA 3189374A CA 3189374 A CA3189374 A CA 3189374A CA 3189374 A1 CA3189374 A1 CA 3189374A1
Authority
CA
Canada
Prior art keywords
curcumin
cytokines
cytokine
disease
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3189374A
Other languages
English (en)
Inventor
Peter P. Sordillo
Lawrence Helson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Signpath Pharma Inc
Original Assignee
Signpath Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/945,195 external-priority patent/US20200360300A1/en
Application filed by Signpath Pharma Inc filed Critical Signpath Pharma Inc
Publication of CA3189374A1 publication Critical patent/CA3189374A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Medical Informatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)

Abstract

La présente invention concerne des procédés et des compositions destinés à atténuer des symptômes ou à traiter un ou plusieurs effets indésirables déclenchés par des maladies infectieuses ou des troubles pathologiques qui déclenchent une importante libération de cytokines chez un sujet, comprenant les étapes suivantes : l'identification du sujet ayant besoin d'une atténuation de symptômes ou du traitement de maladies infectieuses ou de troubles pathologiques qui déclenchent une importante libération de cytokines; et l'administration d'une ou de plusieurs compositions pharmaceutiques comprenant une quantité thérapeutiquement efficace d'un extrait de curcumine, de curcuminoïdes ou de curcumine synthétique (S-curcumine) et de leurs dérivés, et des lipides dissous ou dispersés dans un milieu aqueux ou non aqueux approprié suffisant pour réduire le taux de cytokines chez l'hôte.
CA3189374A 2020-07-31 2021-07-13 Suppression de liberation de cytokine et de choc cytokinique Pending CA3189374A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16/945,195 US20200360300A1 (en) 2014-12-31 2020-07-31 Suppression of Cytokine Release and Cytokine Storm
US16/945,195 2020-07-31
PCT/US2021/041403 WO2022026170A1 (fr) 2020-07-31 2021-07-13 Suppression de libération de cytokine et de choc cytokinique

Publications (1)

Publication Number Publication Date
CA3189374A1 true CA3189374A1 (fr) 2022-02-03

Family

ID=80036956

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3189374A Pending CA3189374A1 (fr) 2020-07-31 2021-07-13 Suppression de liberation de cytokine et de choc cytokinique

Country Status (9)

Country Link
EP (1) EP4188398A1 (fr)
JP (1) JP2023536833A (fr)
KR (1) KR20230026468A (fr)
CN (1) CN116710123A (fr)
AU (1) AU2021315452A1 (fr)
CA (1) CA3189374A1 (fr)
MX (1) MX2023001145A (fr)
TW (1) TW202207907A (fr)
WO (1) WO2022026170A1 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109549925B (zh) * 2012-06-14 2022-06-17 伯尔尼大学 用于治疗细菌感染的定制脂质体
US10286065B2 (en) * 2014-09-19 2019-05-14 Board Of Regents, The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
US20200360300A1 (en) * 2014-12-31 2020-11-19 Signpath Pharma, Inc. Suppression of Cytokine Release and Cytokine Storm
US10739353B2 (en) * 2014-12-31 2020-08-11 Signpath Pharma, Inc. Suppression of cytokine release and cytokine storm
JP2019502753A (ja) * 2015-12-23 2019-01-31 ムーンショット ファーマ エルエルシー ナンセンス変異依存ｍＲＮＡ分解機構の抑制による免疫応答の誘導法

Also Published As

Publication number Publication date
AU2021315452A1 (en) 2023-02-02
CN116710123A (zh) 2023-09-05
EP4188398A1 (fr) 2023-06-07
KR20230026468A (ko) 2023-02-24
WO2022026170A1 (fr) 2022-02-03
TW202207907A (zh) 2022-03-01
MX2023001145A (es) 2023-03-06
JP2023536833A (ja) 2023-08-30

Similar Documents

Publication Publication Date Title
US10739353B2 (en) Suppression of cytokine release and cytokine storm
Li et al. Inhibition of double‐strand DNA‐sensing cGAS ameliorates brain injury after ischemic stroke
Jassam et al. Neuroimmunology of traumatic brain injury: time for a paradigm shift
Mulay et al. Necroinflammation in kidney disease
B Fessler et al. Potential roles of HDAC inhibitors in mitigating ischemia-induced brain damage and facilitating endogenous regeneration and recovery
Sordillo et al. Bifunctional role of pro-inflammatory cytokines after traumatic brain injury
US20200360300A1 (en) Suppression of Cytokine Release and Cytokine Storm
CN110913911A (zh) 用于治疗癌症的组合疗法
US11179412B2 (en) Methods of treating conditions involving elevated inflammatory response
JP2019505579A (ja) 免疫応答を誘導するための方法
CN102439153A (zh) 用于刺激哺乳动物对病原体的先天免疫抵抗力的组合物
Shavit Stein et al. Thrombin inhibition reduces the expression of brain inflammation markers upon systemic LPS treatment
Gilzad-Kohan et al. Anti-inflammatory properties of drugs used to control COVID-19 and their effects on the renin-angiotensin system and angiotensin-converting enzyme-2
HRP960070A2 (en) Use of quinoxaline and protease inhibitors in a composition for the treatment of aids and/or hiv infections
Li et al. Signaling pathways in macrophages: molecular mechanisms and therapeutic targets
Zhang et al. Preclinical and clinical progress for HDAC as a putative target for epigenetic remodeling and functionality of immune cells
Yang et al. Discovery of novel aporphine alkaloid derivative as potent TLR2 antagonist reversing macrophage polarization and neutrophil infiltration against acute inflammation
JP2024516340A (ja) Ｓａｒｓ－ｃｏｖ－２感染の後遺症の予防と治療のためのルミノール
CA3189374A1 (fr) Suppression de liberation de cytokine et de choc cytokinique
Wang et al. Mechanisms of PANoptosis and relevant small-molecule compounds for fighting diseases
CN115052602A (zh) 5-胺基-2,3-二氢-1,4-酞嗪二酮在治疗罕见的慢性发炎性肺病中的用途
WO2021258206A1 (fr) Thérapie à base d'artésunate hydrosoluble pour une infection à coronavirus
Sun et al. CAR‑T cell therapy: A breakthrough in traditional cancer treatment strategies
You et al. p65 siRNA-Loaded Buformin/DNA Nanoprisms Alleviate Acute Lung Injury through Inhibiting NLRP3-Mediated Pyroptosis
US20230263812A1 (en) Compositions and Methods for Treating COVID-19 and/or Acute Respiratory Failure and/or Acute Respiratory Distress Syndrome Using Tetrahydrocannabinol and Compositions Including Same

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230111

EEER Examination request

Effective date: 20230111

EEER Examination request

Effective date: 20230111

EEER Examination request

Effective date: 20230111

EEER Examination request

Effective date: 20230111